CinRx Pharma, LLC - Jan 11, 2022 Form 4 Insider Report for CinCor Pharma, Inc. (CINC)

Role
10%+ Owner
Signature
CinRx Pharma, LLC, By /s/ Jonathan Isaacsohn, CEO
Stock symbol
CINC
Transactions as of
Jan 11, 2022
Transactions value $
$0
Form type
4
Date filed
1/13/2022, 03:40 PM
Previous filing
Jan 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CINC Common Stock Conversion of derivative security +1.22M +50.78% 3.63M Jan 11, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CINC Series A Preferred Stock Conversion of derivative security $0 -2.14M -100% $0.00* 0 Jan 11, 2022 Common Stock 630K Direct F1
transaction CINC Series B Preferred Stock Conversion of derivative security $0 -2.01M -100% $0.00* 0 Jan 11, 2022 Common Stock 592K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.